Immunology, lupus and atheroma

Gr, Hughes

doi:10.1191/096120300678828316

Cited by 9 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with systemic lupus erythematosus (SLE) or antiphospholipid antibody syndrome (APS) are prone to develop arterial complications including arterial thrombosis and atherosclerosis (Roubey, 1996;Haviv, 2000;Hughes, 2000;Urowitz and Gladman, 2000). This fact has attracted attention on the possible role of the autoimmune process in atherosclerosis development.…”

Section: Humoral Immunity In Atherosclerosismentioning

confidence: 99%

Molecular Autoimmunity

2005

View full text Add to dashboard Cite

Section: Humoral Immunity In Atherosclerosismentioning

confidence: 99%

Molecular Autoimmunity

2005

View full text Add to dashboard Cite

“…In-vitro-Untersuchungen zeigten, dass Anti-oxLDL die Akkumulation von oxLDL im Endothel erhöhen [14].…”

Section: Oxidatively Modified Lipoproteins and Their Antibodies In Paunclassified

Oxidativ modifizierte Lipoproteine und deren Antik�rper bei Patienten mit Antiphospholipidsyndrom und Systemischem Lupus erythematodes

et al. 2004

View full text Add to dashboard Cite

The antiphospholipid syndrome (APS) with its typical clinical manifestations of recurrent thrombosis and fetal loss is biochemically defined by the presence of circulating antiphospholipid antibodies (aPL). The disease pattern has raised special interest as a possible link between autoimmunity and atherosclerosis. aPL, oxidized low density lipoproteins (oxLDL), and antibodies to oxLDL (Anti-oxLDL) are suggested to play an important role in atherogenesis. In the present study we compared the serum levels of oxLDL and Anti-oxLDL in APS patients (20 subjects with primary APS; 14 subjects with secondary APS) and nonAPS subjects (24 phenotypically healthy controls samples and 12 patients with systemic lupus erythematosus [SLE]) and investigated associations of the above mentioned parameters with the intima-media thickness (IMT), a clinical surrogate parameter of atherosclerosis.SLE patients with and without APS showed significantly increased levels of Anti-oxLDL as compared to the controls group (p = 0.038 and p = 0.007, respectively). In contrast, oxLDL levels were not significantly different between the controls group and patients. The Anti-oxLDL levels correlated significantly with anticardiolipin (p = 0.002) and beta(2)-glycoprotein I antibodies (p < 0.048), both from IgG isotype. Only SLE patients without APS revealed a significantly elevated production of reactive oxygen species indicating an increased proatherogenic oxidative stress in the circulation (p < 0.002). In the patient groups, the circulating levels of oxLDL and Anti-oxLDL showed no association with atherosclerosis as estimated by IMT. In conclusion, our experimental data do not support the concept of oxidative stress-induced accelerated atherosclerosis in APS patients.

show abstract

The Cardiovascular Burden of Lupus

Schattner¹,

Liang²

2003

Arch Intern Med

View full text Add to dashboard Cite

Immunology, lupus and atheroma

Cited by 9 publications

References 17 publications

Molecular Autoimmunity

Molecular Autoimmunity

Oxidativ modifizierte Lipoproteine und deren Antik�rper bei Patienten mit Antiphospholipidsyndrom und Systemischem Lupus erythematodes

The Cardiovascular Burden of Lupus

Contact Info

Product

Resources

About